Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IN8BIO, Inc. INAB

Healthcare Biotechnology
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400,... see more

Recent & Breaking News (NDAQ:INAB)

IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

GlobeNewswire December 9, 2021

IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer

GlobeNewswire November 16, 2021

IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors

GlobeNewswire November 11, 2021

IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2021

IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO

GlobeNewswire November 4, 2021

IN8bio's Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme

GlobeNewswire October 27, 2021

IN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021

GlobeNewswire October 4, 2021

Engaging Medical Play Sees Stock Price Settle

Stockhouse Editorial September 14, 2021

IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire September 10, 2021

IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire August 30, 2021

IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

GlobeNewswire August 11, 2021

IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors

GlobeNewswire August 4, 2021

IN8bio Announces Pricing of Initial Public Offering

GlobeNewswire July 30, 2021